{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,23]],"date-time":"2026-08-23T17:29:51Z","timestamp":1787506191601,"version":"build-2736575974"},"reference-count":152,"publisher":"SAGE Publications","issue":"5_suppl","license":[{"start":{"date-parts":[[2005,9,1]],"date-time":"2005-09-01T00:00:00Z","timestamp":1125532800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Int J Toxicol"],"published-print":{"date-parts":[[2005,9]]},"abstract":"<jats:p>Niacinamide (aka nicotinamide) and Niacin (aka nicotinic acid) are heterocyclic aromatic compounds which function in cosmetics primarily as hair and skin conditioning agents. Niacinamide is used in around 30 cosmetic formulations including shampoos, hair tonics, skin moisturizers, and cleansing formulations. Niacin is used in a few similar product types. The concentration of use of Niacinamide varies from a low of 0.0001% in night preparations to a high of 3% in body and hand creams, lotions, powders and sprays. Niacin concentrations of use range from 0.01% in body and hand creams, lotions, powders and sprays to 0.1% in paste masks (mud packs). Both ingredients are accepted for use in cosmetics in Japan and the European Union. Both are GRAS direct food additives and nutrient and\/or dietary supplements. Niacinamide may be used in clinical treatment of hypercholesteremia and Niacin in prevention of pellegra and treatment of certain psychological disorders. Both ingredients are readily absorbed from skin, blood, and the intestines and widely distribute throughout the body. Metabolites include N1-methylnicotinamide and N1-methyl-4-pyridone-3-carboxamide. Excretion is primarily through the urinary tract. While Niacinamide ismore toxic than Niacinin acute toxicity studies, both are relatively non-toxic. Short-term oral, parenteral, or dermal toxicity studies did not identify significant irreversible effects. Niacinamide, evaluated in an in vitro test to predict ocular irritation, was not an acute ocular hazard. Animal testing of Niacinamide in rabbits in actual formulations produced mostly non-irritant reactions, with only some marginally irritating responses. Skin irritation tests of up to 2.5% Niacinamide in rabbits produced only marginal irritation. Skin sensitization tests of Niacinamide at 5% during induction and 20% during challenge were negative in guinea pigs. Neither cosmetic ingredient was mutagenic in Ames tests, with or without metabolic activation. Niacinamide and Niacin at 2 mg\/ml were negative in a chromosome aberration test in Chinese hamster ovary cells, but did produce large structural chromosome aberrations at 3 mg\/ml. Niacinamide induced sister chromatid exchanges in Chinese hamster ovary cells, but Niacin did not. Under certain circumstances, Niacinamide can cause an increase in unscheduled DNA synthesis in human lymphocytes treated with UV or a nitrosoguanidine compound. Niacinamide itself was not carcinogenic when administered (1%) in the drinking water of mice. No data on the carcinogenic effect of Niacin were available. Niacinamide can moderate the induction of tumors by established carcinogens. Niacinamide in combination with streptozotocin (a nitrosourea compound) or with heliotrine (a pyrrolizidine alkaloid), produced pancreatic islet tumors. On the other hand, Niacinamide reduced the renal adenomas produced by streptozotocin; and intestinal and bladder tumors induced by a preparation of bracken fern. Niacinamide evaluated in in vitro test systems did affect development, but Niacinamide reduced the reproductive\/developmental toxicity of 2-aminonicotinamide-amino-1,3,4-thiadiazole hydrochloride and urethane. Clinical testing of Niacinamide produced no stinging sensation at concentrations up to 10%, use tests produced no irritation at concentrations up to 5%, and a 21-day cumulative irritation test at concentrations up to 5% resulted in no irritancy. Niacinamide was not a sensitizer, nor was it a photosensitizer. The CIR Expert Panel considered that Niacinamide and Niacin are sufficiently similar from a toxicologic standpoint to combine the available data and reach a conclusion on the safety of both as cosmetic ingredients. Overall, these ingredients are non-toxic at levels considerably higher than would be experienced in cosmetic products. Clinical testing confirms that these ingredients are not significant skin irritants, sensitizers or photosensitizers. While certain formulations were marginal to slight ocular irritants, other formulations were not. Niacinamide, while not carcinogenic alone, can modulate the induction of tumors by certain established carcinogens. The Panel noted that the doses in these studies are high relative to the low concentrations at which Niacinamide is used in cosmetic formulations. In neither case (tumor protection or tumor promotion) are these findings considered relevant to the use of Niacinamide at its current low concentrations of use in cosmetics. Both ingredients were considered safe as used in cosmetics.<\/jats:p>","DOI":"10.1080\/10915810500434183","type":"journal-article","created":{"date-parts":[[2006,4,25]],"date-time":"2006-04-25T08:02:46Z","timestamp":1145952166000},"page":"1-31","source":"Crossref","is-referenced-by-count":35,"title":["Final Report of the Safety Assessment of Niacinamide and Niacin1"],"prefix":"10.1177","volume":"24","member":"179","published-online":{"date-parts":[[2005,9,1]]},"reference":[{"key":"atypb1","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1016\/S0021-9258(18)81324-2","volume":"238","year":"1963","journal-title":"J. Biol. Chem."},{"key":"atypb2","doi-asserted-by":"publisher","DOI":"10.1016\/0003-9861(55)90070-9"},{"key":"atypb3","doi-asserted-by":"publisher","DOI":"10.1016\/0021-9150(73)90070-1"},{"key":"atypb4","first-page":"385","volume":"42","year":"1967","journal-title":"Mayo Clin. Proc."},{"key":"atypb5","doi-asserted-by":"publisher","DOI":"10.1016\/0026-0495(73)90207-2"},{"key":"atypb6","doi-asserted-by":"publisher","DOI":"10.1177\/070674377101600506"},{"key":"atypb7","first-page":"1353","volume":"69","year":"1982","journal-title":"JNCI"},{"key":"atypb8","first-page":"362","volume":"101","year":"1951","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"atypb9","first-page":"65","volume":"7","year":"1973","journal-title":"Te r a-tology"},{"key":"atypb10","doi-asserted-by":"publisher","DOI":"10.1002\/jps.2600640345"},{"key":"atypb11","first-page":"416","volume":"16","year":"1961","journal-title":"Geriatrics"},{"key":"atypb12","doi-asserted-by":"publisher","DOI":"10.1016\/0002-9343(61)90221-2"},{"key":"atypb13","first-page":"49","volume":"8","year":"1953","journal-title":"British Journal of Pharmacology"},{"key":"atypb14","unstructured":"BIBRA International. 1998. Toxicity profile: Niacinamide. Unpublished data submitted by Procter & Gamble. (12 pages)."},{"key":"atypb15","unstructured":"Bionetics Research Labs, Inc. 1968. Evaluation of carcinogenic, teratogenic, and mutagenic activities of selected pesticides and industrial chemicals. Volume II. Teratogenic study in mice and rats. NTIS Report No. PB223160."},{"key":"atypb16","doi-asserted-by":"publisher","DOI":"10.3181\/00379727-62-15356"},{"key":"atypb17","doi-asserted-by":"publisher","DOI":"10.1002\/jps.2600741008"},{"key":"atypb18","first-page":"502","volume":"34","year":"1959","journal-title":"Proc. Staff Meeting Mayo Clin."},{"key":"atypb19","doi-asserted-by":"publisher","DOI":"10.3181\/00379727-124-31878"},{"key":"atypb20","first-page":"1817","volume":"236","year":"1959","journal-title":"J. Biol. Chem."},{"key":"atypb21","doi-asserted-by":"crossref","first-page":"2096","DOI":"10.1016\/S0021-9258(18)64135-3","volume":"236","year":"1961","journal-title":"J. Biol. Chem."},{"key":"atypb22","doi-asserted-by":"publisher","DOI":"10.1177\/000331977202300105"},{"key":"atypb23","first-page":"423","volume":"15","year":"1960","journal-title":"Geriatrics"},{"key":"atypb24","doi-asserted-by":"publisher","DOI":"10.3181\/00379727-38-9806"},{"key":"atypb25","doi-asserted-by":"publisher","DOI":"10.1097\/00004836-198710000-00022"},{"key":"atypb26","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1542\/peds.92.1.78","volume":"92","year":"1993","journal-title":"Pediatrics"},{"key":"atypb27","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1016\/S0021-9258(19)45675-5","volume":"247","year":"1972","journal-title":"J. Biol. Chem."},{"key":"atypb28","doi-asserted-by":"publisher","DOI":"10.3109\/02844318909075114"},{"key":"atypb29","unstructured":"Committee of Revision of the United States Pharmacopeial Convention (USP), Inc. 1995. The United States Pharmacopeia. 23rd ed. Rockville, MD: USP Convention, Inc. p. 1080-1082."},{"key":"atypb30","unstructured":"Cosmetic, Toiletry, and Fragrance Association (CTFA). 2001. Concentration of use of Niacin and Niacinamide as a function of product type. Unpublished data submitted by CTFA."},{"key":"atypb31","first-page":"289","volume":"33","year":"1975","journal-title":"Niacin. Nutr. Rev."},{"key":"atypb32","first-page":"1047","volume":"71","year":"1976","journal-title":"Med. Klin."},{"key":"atypb33","doi-asserted-by":"publisher","DOI":"10.1007\/BF01070732"},{"key":"atypb34","doi-asserted-by":"publisher","DOI":"10.1016\/S0025-6196(12)61171-9"},{"key":"atypb35","unstructured":"European Commission. 2002 The rules governing cosmetic products in the European Union. Volume 1. Cosmetics legislation-Cosmetic products. Accessed January 9, 2002 http:\/\/dg3.eudra.org\/F3\/home.html."},{"key":"atypb36","doi-asserted-by":"publisher","DOI":"10.1016\/0024-3205(80)90638-4"},{"key":"atypb37","unstructured":"Federation of American Societies for Experimental Biology (FASEB). 1979. Evaluation of the health aspects niacin and niacinamide as food ingredients. NTIS Report No. PB80112030."},{"key":"atypb38","doi-asserted-by":"publisher","DOI":"10.1111\/1523-1747.ep12259184"},{"key":"atypb39","unstructured":"Food and Drug Administration (FDA). 1984. Cosmetic product formulation data and frequency of use data.\n                      FDA database.\n                      Washington, DC: FDA."},{"key":"atypb40","doi-asserted-by":"publisher","DOI":"10.1111\/1523-1747.ep12533356"},{"key":"atypb41","doi-asserted-by":"publisher","DOI":"10.1136\/bjo.79.1.54"},{"key":"atypb42","doi-asserted-by":"publisher","DOI":"10.1080\/01635589709514618"},{"key":"atypb43","doi-asserted-by":"publisher","DOI":"10.1093\/ajcn\/6.5.479"},{"key":"atypb44","first-page":"55","volume":"199","year":"1988","journal-title":"Mutat. Res."},{"key":"atypb45","doi-asserted-by":"publisher","DOI":"10.1097\/00000441-195901000-00003"},{"key":"atypb46","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2133.1988.tb02572.x"},{"key":"atypb47","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1016\/S0021-9258(18)44953-8","volume":"146","year":"1942","journal-title":"J. Biol. Chem."},{"key":"atypb48","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1016\/S0021-9258(18)71957-1","volume":"154","year":"1944","journal-title":"J. Biol. Chem."},{"key":"atypb49","doi-asserted-by":"publisher","DOI":"10.1016\/0002-9343(91)90122-E"},{"key":"atypb50","doi-asserted-by":"publisher","DOI":"10.1007\/s001250051113"},{"key":"atypb51","doi-asserted-by":"publisher","DOI":"10.3181\/00379727-97-23769"},{"key":"atypb52","doi-asserted-by":"publisher","DOI":"10.1016\/0167-8140(93)90133-S"},{"key":"atypb53","doi-asserted-by":"publisher","DOI":"10.1016\/0278-6915(92)90056-Q"},{"key":"atypb54","unstructured":"Informatics. 1974. Monograph on niacin. (Submitted by FDA in response to an FOI request-2000, 416 pages)."},{"key":"atypb55","doi-asserted-by":"publisher","DOI":"10.1016\/0278-6915(84)90271-0"},{"key":"atypb56","doi-asserted-by":"publisher","DOI":"10.1016\/0165-1110(88)90023-1"},{"key":"atypb57","unstructured":"Japan Ministry of Health, Labor, and Welfare (MHLW). 2000. Notification No. 990. MHLW, Parmaceutical and Medical Safety Bureau, Inspection and Guidance Division, Tokyo: Japan."},{"key":"atypb58","doi-asserted-by":"publisher","DOI":"10.1016\/S0167-8140(96)01896-8"},{"key":"atypb59","first-page":"151","volume":"49","year":"1986","journal-title":"Int. J. Radiat. Biol."},{"key":"atypb60","doi-asserted-by":"publisher","DOI":"10.1097\/00004836-199304000-00015"},{"key":"atypb61","first-page":"207","volume":"3","year":"1983","journal-title":"Anticancer Res."},{"key":"atypb62","doi-asserted-by":"crossref","first-page":"3277","DOI":"10.1016\/S0021-9258(18)93125-X","volume":"244","year":"1969","journal-title":"J. Biol. Chem."},{"key":"atypb63","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1016\/S0021-9258(18)56008-7","volume":"190","year":"1951","journal-title":"J. Biol. Chem."},{"key":"atypb64","volume-title":"Hazardous Chemicals Desk Reference","year":"1993"},{"key":"atypb65","unstructured":"Litton Bionetics, Inc. 1977a. Mutagenicity evaluation of FDA 75-86 niacinamide. (Submitted by FDA in response to an FOI request-2000; 46 pages)."},{"key":"atypb66","unstructured":"Litton Bionetics, Inc. 1977b. Mutagenicity evaluation of FDA 75-88 niacin (nicotinic acid). (Submitted by FDA in response to an FOI request-2000; 46 pages)."},{"key":"atypb67","first-page":"243","volume":"42","year":"1957","journal-title":"Nebr. State Med. J."},{"key":"atypb68","doi-asserted-by":"publisher","DOI":"10.1001\/archderm.1983.01650340046018"},{"key":"atypb69","first-page":"427","volume":"46","year":"1974","journal-title":"Clin. Sci. Mol. Med."},{"key":"atypb70","doi-asserted-by":"publisher","DOI":"10.1093\/humrep\/15.1.157"},{"key":"atypb71","doi-asserted-by":"publisher","DOI":"10.1016\/S0161-6420(88)33073-3"},{"key":"atypb72","doi-asserted-by":"publisher","DOI":"10.1016\/S0006-291X(81)80119-2"},{"key":"atypb73","doi-asserted-by":"publisher","DOI":"10.1002\/tera.1420290213"},{"issue":"4","key":"atypb74","first-page":"293","volume":"17","year":"1969","journal-title":"Koshu Eiseiin Kenkyu Hokoku."},{"key":"atypb75","unstructured":"National Library of Medicine (NLM). 2000. Medical Subject Headings (MeSH): Niacin and niacinamide notes.\n                      MeSH Database.\n                      Bethesda: NLM."},{"key":"atypb76","unstructured":"National Toxicology Program (NTP). 2000. Entry on niacinamide and niacin.\n                      NTP database.\n                      Bethesda: National Library of Medicine."},{"key":"atypb77","doi-asserted-by":"publisher","DOI":"10.1016\/S0025-6196(12)60393-0"},{"key":"atypb78","doi-asserted-by":"publisher","DOI":"10.1016\/S0006-291X(80)80009-X"},{"key":"atypb79","doi-asserted-by":"publisher","DOI":"10.1080\/01635588109513707"},{"key":"atypb80","doi-asserted-by":"publisher","DOI":"10.1001\/jama.1957.02980210030009"},{"key":"atypb81","doi-asserted-by":"publisher","DOI":"10.1097\/00007611-198302000-00023"},{"key":"atypb82","doi-asserted-by":"publisher","DOI":"10.1093\/jn\/40.3.453"},{"key":"atypb83","doi-asserted-by":"publisher","DOI":"10.1259\/bjr.70.830.9135442"},{"key":"atypb84","doi-asserted-by":"crossref","first-page":"2367","DOI":"10.1016\/S0021-9258(18)96630-5","volume":"241","year":"1966","journal-title":"J. Biol. Chem."},{"key":"atypb85","first-page":"767","volume":"73","year":"1984","journal-title":"J. Natl. Cancer Inst."},{"key":"atypb86","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1016\/S0021-9258(18)64875-6","volume":"225","year":"1957","journal-title":"J. Biol. Chem."},{"key":"atypb87","doi-asserted-by":"crossref","unstructured":"Procter and Gamble. 1997. A low volume eye irritation study in rabbits with CT0011.01, niacinamide. Unpublished data. (39 pages).","DOI":"10.1016\/S0294-3506(97)88271-3"},{"key":"atypb88","unstructured":"Procter and Gamble. 1998a. Physicochemical properties and topical delivery rate of niacinamide. Unpublished data. (12 pages)."},{"key":"atypb89","unstructured":"Procter and Gamble. 1998b. Human repeat insult patch test with 20% niacinamide cream. Unpublished data. (9 pages)."},{"key":"atypb90","unstructured":"Procter and Gamble. 1999a. Human repeat insult patch test with 2% niacinamide cream. Unpublished data. (11 pages)."},{"key":"atypb91","unstructured":"Procter and Gamble. 1999b. Human repeat insult patch test with 5% niacinamide cream. Unpublished data. (11 pages)."},{"key":"atypb92","unstructured":"Procter and Gamble. 1999c. A single-blind, dermatologic and ophthalmologic safety evaluation of facial moisturizer products containing niacinamide. Unpublished data. (12 pages)."},{"key":"atypb93","unstructured":"Procter and Gamble. 1999d. Phototoxicity study of a liquid make-up containing niacinamide. Unpublished data. (11 pages)."},{"key":"atypb94","unstructured":"Procter and Gamble. 1999e. Photoallergy study of a liquid make-up containing niacinamide. Unpublished data. (12 pages)."},{"key":"atypb95","unstructured":"Procter and Gamble. 2000a. 21-Day cumulative human irritation patch test of products containing niacinamide. Unpublished data. (41 pages)."},{"key":"atypb96","unstructured":"Procter and Gamble. 2000b. Phototoxicity study of a lipstick containing niacinamide. Unpublished data. (12 pages)."},{"key":"atypb97","unstructured":"Procter and Gamble. 2000c. Tissue equivalent assay with EpiOculara cultures using products containing 10% niacinamide. Unpublished data. (13 pages)."},{"key":"atypb98","unstructured":"Procter and Gamble. 2000d. Tissue equivalent assay with EpiOculara cultures using facial moisturizers containing 2 and 3.5% niacinamide. Unpublished data. (13 pages)."},{"key":"atypb99","unstructured":"Procter and Gamble. 2001. Human assay to evaluate the comedogenic potential of a test article containing niacinamide. Unpublished data. (7 pages)."},{"key":"atypb100","doi-asserted-by":"publisher","DOI":"10.1002\/jps.2600570617"},{"key":"atypb101","doi-asserted-by":"publisher","DOI":"10.1016\/S0003-9861(66)81050-0"},{"key":"atypb102","doi-asserted-by":"publisher","DOI":"10.3181\/00379727-137-35561"},{"key":"atypb103","doi-asserted-by":"publisher","DOI":"10.3181\/00379727-151-39209"},{"key":"atypb104","doi-asserted-by":"publisher","DOI":"10.1042\/bj0530286"},{"key":"atypb105","doi-asserted-by":"publisher","DOI":"10.1093\/jn\/82.1.83"},{"key":"atypb106","doi-asserted-by":"publisher","DOI":"10.1080\/09553009014550871"},{"key":"atypb107","doi-asserted-by":"publisher","DOI":"10.1001\/jama.1959.63010170008010c"},{"key":"atypb108","first-page":"267","volume":"96","year":"1962","journal-title":"Calif. Med."},{"key":"atypb109","first-page":"252","volume":"16","year":"1964","journal-title":"Br. J. Cancer"},{"key":"atypb110","first-page":"809","volume":"45","year":"1985","journal-title":"Cancer Research"},{"key":"atypb111","doi-asserted-by":"publisher","DOI":"10.1093\/carcin\/7.1.175"},{"key":"atypb112","first-page":"1833","volume":"405","year":"1977","journal-title":"Cancer"},{"key":"atypb113","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-4362.1995.tb04449.x"},{"key":"atypb114","doi-asserted-by":"publisher","DOI":"10.3177\/jnsv.36.87"},{"key":"atypb115","doi-asserted-by":"publisher","DOI":"10.1002\/jsscb.1981.380160308"},{"key":"atypb116","first-page":"251","volume":"5","year":"1964","journal-title":"J. Nucl. Med."},{"key":"atypb117","doi-asserted-by":"publisher","DOI":"10.1038\/clpt.1991.104"},{"key":"atypb118","doi-asserted-by":"publisher","DOI":"10.1001\/jama.1974.03230270046027"},{"key":"atypb119","doi-asserted-by":"publisher","DOI":"10.1093\/jn\/116.12.2409"},{"key":"atypb120","first-page":"491","volume":"14","year":"1986","journal-title":"Nucl. Med. Biol."},{"key":"atypb121","first-page":"71","volume":"2","year":"1982","journal-title":"Anticancer Res."},{"key":"atypb122","doi-asserted-by":"publisher","DOI":"10.1016\/S0015-0282(16)56534-0"},{"key":"atypb123","doi-asserted-by":"publisher","DOI":"10.1113\/expphysiol.1962.sp001582"},{"key":"atypb124","unstructured":"Unilever. 1998a. Niacinamide: Safety assessment (Document number D97\/059), section 5. safety assessment of topically applied niacinamide. Unpublished data submitted by CTFA. (14 pages)."},{"key":"atypb125","unstructured":"Unilever. 1998b. Nicotinamide: percutaneous absorption in the rat (Study PCW 76 1208). Unpublished data submitted by CTFA. (8 pages)."},{"key":"atypb126","unstructured":"Unilever. 1998c. Nicotinamide-(carbonyl-C): in vitro skin absorption study (Study SA960335). Unpublished data submitted by CTFA.(8 pages)."},{"key":"atypb127","unstructured":"Unilever. 1998d. Niacinamide: in vitro skin penetration study (Study SA970093). Unpublished data submitted by CTFA. (10 pages)."},{"key":"atypb128","unstructured":"Unilever. 1998e. Nicotinamide: Ultraviolet and visible absorption spectrum (Study AS 77.06). Unpublished data submitted by CTFA. (4 pages)."},{"key":"atypb129","unstructured":"Unilever. 1998f. Nicotinamide: assessment of toxicity to cultured macrophages (Study PCW 78 1245). Unpublished data submitted by CTFA. (5 pages)."},{"key":"atypb130","unstructured":"Unilever. 1998g. Nicotinamide: four-week skin application test on mice (Study SPM 80\/1-Report PES 84 1025). Unpublished data submitted by CTFA. (23 pages)."},{"key":"atypb131","unstructured":"Unilever. 1998h. Nicotinamide: thirteen-week skin application test on mice (Study PhC 80\/2-Report PES 84 1031). Unpublished data submitted by CTFA. (16 pages)."},{"key":"atypb132","unstructured":"Unilever. 1998i. Skin creams containing nicotinamide: eye irritation to the rabbit (Study RE76\/143 B and C). Unpublished data submitted by CTFA. (10 pages)."},{"key":"atypb133","unstructured":"Unilever. 1998j. Skin cream containing nicotinamide: phototoxicity study in rats (Study PHI 77\/2). Unpublished data submitted by CTFA. (7 pages)."},{"key":"atypb134","unstructured":"Unilever. 1998k. Nicotinamide: skin irritation in rabbits-intradermal injection test (Study INJ77.06A). Unpublished data submitted by CTFA. (11 pages)."},{"key":"atypb135","unstructured":"Unilever. 1998l. Nicotinamide: skin sensitization in guinea pigs (Study 2"},{"key":"atypb136","unstructured":"Unilever. 1998m. Niacinamide: mutagenicity test (Study MUT\/SMS 232). Unpublished data submitted by CTFA. (4 pages)."},{"key":"atypb137","unstructured":"Unilever. 1998n. Cream and lotion containing niacinamide: human skin irritation study (covered patch test) (Study HP970072). Unpublished data submitted by CTFA. (7 pages)."},{"key":"atypb138","unstructured":"Unilever. 1998o. Skin cream containing 3% niacinamide: human skin irritation study (covered patch test) (Study HP970108). Unpublished data submitted by CTFA. (7 pages)."},{"key":"atypb139","unstructured":"Unilever. 1998p. Skin cream containing 3% niacinamide: skin irritation in humans simulated use test (Study ST870524). Unpublished data submitted by CTFA. (7 pages)."},{"key":"atypb140","unstructured":"Unilever. 1998q. Nicotinamide: skin irritation in humans simulated use test (Study ST742). Unpublished data submitted by CTFA. (8 pages)."},{"key":"atypb141","unstructured":"Unilever. 1998r. Cream and lotion containing niacinamide: sting test in humans (Study HS970096). Unpublished data submitted by CTFA. (7 pages)."},{"key":"atypb142","unstructured":"Unilever. 1998s. Niacinamide: sting test in humans (Study HS970109). Unpublished data submitted by CTFA. (7 pages)."},{"key":"atypb143","unstructured":"Unilever. 1998t. Nicotinamide: sting testinhumans (Study ST740). Unpublished data submitted by CTFA. (7 pages)."},{"key":"atypb144","unstructured":"Unilever. 2001. Niacinamide UV absorption study clarification. Unpublished data submitted by CTFA. (2 pages)."},{"key":"atypb145","first-page":"95","volume":"65","year":"1939","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"atypb146","doi-asserted-by":"publisher","DOI":"10.1016\/0006-291X(79)91156-2"},{"key":"atypb147","doi-asserted-by":"publisher","DOI":"10.1016\/0024-3205(96)00190-7"},{"key":"atypb148","volume-title":"International Cosmetic Ingredient Dictionary and Handbook","year":"2000"},{"key":"atypb149","doi-asserted-by":"publisher","DOI":"10.1016\/0165-1161(89)90005-8"},{"key":"atypb150","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM197311292892208"},{"key":"atypb151","doi-asserted-by":"publisher","DOI":"10.1016\/0041-008X(92)90223-F"},{"key":"atypb152","first-page":"2801","volume":"56","year":"1996","journal-title":"Cancer Res."}],"container-title":["International Journal of Toxicology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1080\/10915810500434183","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1080\/10915810500434183","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T10:22:14Z","timestamp":1777458134000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1080\/10915810500434183"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2005,9]]},"references-count":152,"journal-issue":{"issue":"5_suppl","published-print":{"date-parts":[[2005,9]]}},"alternative-id":["10.1080\/10915810500434183"],"URL":"https:\/\/doi.org\/10.1080\/10915810500434183","relation":{},"ISSN":["1091-5818","1092-874X"],"issn-type":[{"value":"1091-5818","type":"print"},{"value":"1092-874X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2005,9]]}}}